Older adults continue to be left out of #clinicaltrials, however National Cancer Institute NIH U.S. FDA and ASCO are working to fix this, a new JAMA reports. jamanetwork.com/journals/jama/…

Viewpoint highlights neuroendocrine tumors are rising rapidly in incidence, now 2nd most common GI cancer after colorectal, but research & treatments have been limited – time to dedicate more effort to advancing field & options for pts ja.ma/2Nr2Kq7 #GICSM

The tumour microenvironment (TME) highly influences the growth and spread of tumours. The complement system plays a major & complex role. Check out this review Nature Reviews Cancer nature.com/articles/s4156…

Apparently my 5 year old would bring an IPad if she were on the Mayflower. When her teacher asked her why, she said so she could go on Amazon if she needed anything. Oh boy...🤦🏽‍♂️ #HappyThanksgiving

Lights, camera, action! Filming our next #CME molecular tumor board. Should be out early 2020! #PrecisionMedicine #PrecisionOncology #tumorboard #innovation #patientcare @CancerCenter #CTCACME

More evidence demonstrating cancer patients are not benefiting from #precisionmedicine. Only about half of #coloncancer patients get appropriate genomic testing. We need to do better for our patients. JCO Precision Oncology bit.ly/2M9Rm0K

Looking forward to gaining more insights in #precisionmedicine, #AI, #genomics and more at #PMWC20

In a recent article for Oncology Times, Dr. Ankur Parikh shared how @CancerCenter is managing #genomic #data and improving #precisionmedicine programs. Read here: bit.ly/2wYmV9H

Fascinating - compared different search engines for lit review; come down the rabbit hole with me on this #tweetorial on how to write a great peer review, with a focus on lit review search, inspired by a recent Radiology article by Editor-in-Chief Dr. Bluemke. 1/13

FDA Approves First-Line Immunotherapy for Patients with MSI-H/dMMR Metastatic Colorectal Cancer | FDA #colorectalcancer #crcsm #immunotherapy fda.gov/news-events/pr…

Join me today (8/11) for a Facebook Live event at 3pm EST as I sit down with CTCA President and CEO Pat Basu, MD, MBA talking about everything #immunotherapy in #cancercare. Submit your questions live (follow @CancerCenter on FB) #FocusOnCancer

In the NCI-MATCH trial, dabrafenib and trametinib resulted in an ORR of 38%, with some response lasting >2 years, in a mixed histology, pretreated cohort of pts with BRAFV600E-mutated cancers outside of currently approved indications: ascopubs.org/doi/full/10.12… #caxtx #medonc

As #BloodCancerAwarenessMonth comes to an end see some of my tips if you have been recently diagnosed with chronic lymphocytic leukemia (#CLL) in Healthgrades #bloodcancer healthgrades.com/right-care/leu…

If you need #CME check out part III of our Molecular Tumor Board series for 2020. This one has some great cases in #GI cancers and #lungcancer. @CancerCenter mycme.com/courses/molecu…

Appreciate the discussion of our #precisionmedicine program and #clinicaltrials with Philly Mag. Great article highlighting all the innovative advances in cancer treatment here in #philly! @CancerCenter phillymag.com/healthcare-new…

This is my latest Op-Ed on how #COVID19 has changed #cancer care. This pandemic has disrupted our lives and especially the care for all #patients, including those with cancer - but it has also brought us together in new, #innovative ways. #WorldCancerDay managedhealthcareexecutive.com/view/covid-19-…

Thank you American College of Osteopathic Family Physicians and everyone who tuned in to learn about updates in #cancer screening as well as the huge impact #COVID19 has had on screening. #ACOFP21 is always a fun conference to be a part of! #CME #medtwitter @CancerCenter

Thrilled to announce I have joined Sidney Kimmel Comprehensive Cancer Center Jefferson Health - Abington Jefferson Health – Northeast as associate medical director of #PrecisionMedicine! Looking forward to improving access to #genomictesting and #clinicaltrials for our patients!

Thanks for the spotlight! Sidney Kimmel Comprehensive Cancer Center Jefferson Health - Abington Jefferson Health – Northeast #precisionmedicine

Does high tumor mutational burden (#TMB) impact immunotherapy outcomes in #NSCLC? This has been a challenging biomarker to interpret and incorporate into clinical practice. We looked at >1500 patients w/NSCLC treated with PD-(L)1 inhibitors: ja.ma/3Qrvf5y in JAMA Oncology.